CONV-01-alpha + PSMA I&T

N/A

Report date: 2025/11/25 15:56:54

Base Information

Drug NameCONV-01-alpha + PSMA I&T

Drug Alias NameCONV 01-α and PSMA I&T

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225Ac +[5]

Mechanisms of ActionRadionuclide imaging enhancersIonising radiation emittersAnti-PSMA

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesConvergent Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesConvergent Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A